pipette
ESEspañol

Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis

Dana V. Rizk, Jonathan Barratt, Yusuke Suzuki, Hong Zhang, Muh Geot Wong, Adrian Liew, Richard A. Lafayette, Vladimı́r Tesař, Hernán Trimarchi, Kevin Carroll, Ian S.D. Roberts, Vivekanand Jha, Alejandra Quevedo, Seung Hyeok Han, Rosnawati Yahya, Chee Kay Cheung, Raja Ramachandran, Michael Walsh, Bobby Chacko, Manuel Praga, JinBor Chen, José Suassuna, Jing Xia, Lokesh N. Shah, Vlado Perkovic

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
ConclusionsAmong patients with IgA nephropathy, treatment with sibeprenlimab stabilized the eGFR slope over 24 months, a finding consistent with a reduced risk of kidney-function decline.

Appeared: Saturday, October 24. New England Journal of Medicine. Peer-reviewed journal.

DOI: 10.1056/nejmoa2609127